SG11202003112QA - Methods for selectively expanding cells expressing a tcr with a murine constant region - Google Patents
Methods for selectively expanding cells expressing a tcr with a murine constant regionInfo
- Publication number
- SG11202003112QA SG11202003112QA SG11202003112QA SG11202003112QA SG11202003112QA SG 11202003112Q A SG11202003112Q A SG 11202003112QA SG 11202003112Q A SG11202003112Q A SG 11202003112QA SG 11202003112Q A SG11202003112Q A SG 11202003112QA SG 11202003112Q A SG11202003112Q A SG 11202003112QA
- Authority
- SG
- Singapore
- Prior art keywords
- tcr
- methods
- constant region
- cells expressing
- murine constant
- Prior art date
Links
- 241001529936 Murinae Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
- A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762568339P | 2017-10-05 | 2017-10-05 | |
PCT/US2018/052432 WO2019070435A1 (en) | 2017-10-05 | 2018-09-24 | Methods for selectively expanding cells expressing a tcr with a murine constant region |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003112QA true SG11202003112QA (en) | 2020-05-28 |
Family
ID=63841049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003112QA SG11202003112QA (en) | 2017-10-05 | 2018-09-24 | Methods for selectively expanding cells expressing a tcr with a murine constant region |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200254018A1 (en) |
EP (2) | EP4269595A3 (en) |
JP (2) | JP2020535832A (en) |
KR (1) | KR20200064107A (en) |
CN (1) | CN111417720A (en) |
AU (1) | AU2018345400A1 (en) |
CA (1) | CA3077595A1 (en) |
ES (1) | ES2960313T3 (en) |
FI (1) | FI3692140T3 (en) |
IL (1) | IL273698A (en) |
MA (1) | MA50748A (en) |
SG (1) | SG11202003112QA (en) |
WO (1) | WO2019070435A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230150336A (en) | 2021-02-25 | 2023-10-30 | 알로노스 테라퓨틱스 인코포레이티드 | Recombinant vector containing polycistronic expression cassette and method of using same |
WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2202310T3 (en) * | 1991-12-13 | 2004-04-01 | Xoma Corporation | METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES. |
EP0873399A4 (en) * | 1995-09-05 | 2000-07-19 | Gen Hospital Corp | Monoclonal lymphocytes and methods of use |
JP2003276960A (en) * | 2002-03-26 | 2003-10-02 | Mitsubishi Electric Corp | Elevator control system |
WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
CN105021814B (en) * | 2003-11-10 | 2018-02-16 | 阿尔特生物科学公司 | Soluble TCR molecules and application thereof |
DK2016102T3 (en) * | 2006-05-03 | 2012-07-02 | Us Gov Health & Human Serv | Chimeric T cell receptors and associated materials and methods of use |
AU2008206442B2 (en) | 2007-01-12 | 2012-10-18 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | gp100-specific T cell receptors and related materials and methods of use |
WO2010088160A1 (en) | 2009-01-28 | 2010-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
AU2011305817B2 (en) | 2010-09-21 | 2014-12-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SSX-2 T cell receptors and related materials and methods of use |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
ES2718474T3 (en) | 2012-05-22 | 2019-07-02 | Us Health | Murine T-cell receptors anti-NY-ESO-1 |
AU2013315391B2 (en) * | 2012-09-14 | 2017-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
US9822162B2 (en) * | 2013-07-15 | 2017-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 E6 T cell receptors |
KR102618267B1 (en) * | 2014-05-29 | 2023-12-27 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Anti-human papillomavirus 16 e7 t cell receptors |
EP3848456A1 (en) * | 2014-10-02 | 2021-07-14 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
AU2015348198A1 (en) * | 2014-11-20 | 2017-06-08 | Umc Utrecht Holding B.V. | Use of antibodies for enrichment of engineered T cells with exogenous immune receptors and antibodies for use in depletion of engineered T cells |
-
2018
- 2018-09-24 EP EP23185846.5A patent/EP4269595A3/en active Pending
- 2018-09-24 KR KR1020207012314A patent/KR20200064107A/en unknown
- 2018-09-24 JP JP2020519092A patent/JP2020535832A/en active Pending
- 2018-09-24 CA CA3077595A patent/CA3077595A1/en active Pending
- 2018-09-24 FI FIEP18786145.5T patent/FI3692140T3/en active
- 2018-09-24 MA MA050748A patent/MA50748A/en unknown
- 2018-09-24 AU AU2018345400A patent/AU2018345400A1/en active Pending
- 2018-09-24 ES ES18786145T patent/ES2960313T3/en active Active
- 2018-09-24 CN CN201880076862.9A patent/CN111417720A/en active Pending
- 2018-09-24 US US16/652,948 patent/US20200254018A1/en active Pending
- 2018-09-24 WO PCT/US2018/052432 patent/WO2019070435A1/en active Application Filing
- 2018-09-24 SG SG11202003112QA patent/SG11202003112QA/en unknown
- 2018-09-24 EP EP18786145.5A patent/EP3692140B1/en active Active
-
2020
- 2020-03-30 IL IL273698A patent/IL273698A/en unknown
-
2023
- 2023-12-26 JP JP2023220106A patent/JP2024050551A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3077595A1 (en) | 2019-04-11 |
ES2960313T3 (en) | 2024-03-04 |
EP4269595A2 (en) | 2023-11-01 |
WO2019070435A8 (en) | 2020-01-30 |
EP4269595A3 (en) | 2023-12-06 |
US20200254018A1 (en) | 2020-08-13 |
AU2018345400A1 (en) | 2020-05-07 |
CN111417720A (en) | 2020-07-14 |
WO2019070435A1 (en) | 2019-04-11 |
JP2024050551A (en) | 2024-04-10 |
MA50748A (en) | 2020-08-12 |
EP3692140A1 (en) | 2020-08-12 |
FI3692140T3 (en) | 2023-10-11 |
EP3692140B1 (en) | 2023-07-19 |
IL273698A (en) | 2020-05-31 |
KR20200064107A (en) | 2020-06-05 |
JP2020535832A (en) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271435A (en) | T cell receptors | |
IL262144A (en) | T cell receptors | |
IL262124A (en) | T cell receptors | |
IL262128A (en) | T cell receptors | |
IL262146A (en) | T cell receptors | |
IL273915A (en) | Cell | |
GB201813178D0 (en) | Cell | |
GB201713078D0 (en) | T Cell Modification | |
GB201707783D0 (en) | Cell | |
GB201707779D0 (en) | Cell | |
GB201602592D0 (en) | Cellular device cell selection | |
PL3340368T3 (en) | Battery cell including phase change material | |
HUE064591T2 (en) | T cell receptors | |
GB201720949D0 (en) | Cell | |
IL273698A (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
GB201714180D0 (en) | Transduced cell cryoformulation | |
GB201710655D0 (en) | Electrochemical cell | |
GB2574854B (en) | Cell selection procedures | |
GB201807693D0 (en) | Cell | |
GB201711384D0 (en) | A stress cell | |
GB201816399D0 (en) | Cell | |
GB201805918D0 (en) | Cell | |
GB201714718D0 (en) | Cell | |
IL267130A (en) | T cell receptors with improved pairing | |
GB201810070D0 (en) | Cell |